841 results about "Glycoprotein" patented technology

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The invention provides an anti-beta2-glycoprotein I antibody detection reagent and a chemiluminescence detection kit, and the anti-beta2-glycoprotein I antibody detection reagent comprises a biotin-labeled beta2-glycoprotein I antigen prepared by reacting biotin connected with an LPETG label with the beta2-glycoprotein I antigen under the catalytic action of Sortase A enzyme. The N terminal of the beta2-glycoprotein I antigen is labeled with the biotin with a specific label in a fixed point manner, all amino acid sequence regions (structural domains I-V) of the beta2-glycoprotein I antigen are not influenced, and meanwhile, the purity of a connection product is high, the difference between batches is small, and the method is suitable for large-scale production. The positive detection rate and the detection result accuracy of the anti-beta2-glycoprotein I antibody magnetic particle chemiluminescence detection kit can be improved, and the difference between batches can be reduced.

The invention relates to the technical field of stem cells, in particular to a lentivirus envelope plasmid combination and application thereof, a lentivirus and a packaging method thereof and a method for transduction of hematopoietic stem cells. The invention provides an envelope plasmid combination for lentivirus packaging, which is composed of lentivirus packaging plasmids containing VSVG glycoprotein and lentivirus packaging plasmids containing BaEV glycoprotein in a ratio of 3: 7. The invention further provides a method for transduction of the hematopoietic stem cells by the lentivirus, the method is simple and convenient to operate, the long-term dryness of the hematopoietic stem cells in vitro can be maintained, efficient and stable transduction of the hematopoietic stem cells can be realized, and the transduction rate is greater than 90%. The lentivirus transduction method hematopoietic stem cells can be used for hematopoietic stem cell gene therapy hematopoietic system genetic diseases, such as severe combined immunodeficiency, beta-thalassemia and sickle cell disease, Wiskott-Aldrich syndrome and the like, and the application prospect is good.

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The application discloses a method for recovering active glycoprotein Patatin from potato starch processing waste juice, and belongs to the technical field of protein extraction. The method is characterized in that the active Patatin protein is efficiently separated by using the combination of ammonium sulfate fractionation precipitation, anion exchange chromatography, Con A affinity chromatography and gel chromatography, and the obtained Patatin protein retains the original protein structure and biological function activity. Compared with the prior art, the method has better separation purity and higher efficiency, and the obtained Patatin protein has complete protein higher structure and function activity, and has a better application scene.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The invention relates to the technical field of biomedical materials and tissue engineering, in particular to a bionic skin model for drug transdermal release research. The hydrogel has skin-like epidermis and dermis structures, the epidermis structure is composed of an electrostatic spinning high-molecular polymer, and the dermis structure is composed of an interpenetrating hydrogel skeleton formed by interweaving polysaccharide, protein and lipid. By adjusting the thickness and composition of the bionic skin, the bionic skin can show a transdermal drug release behavior similar to that of traditional in-vitro skin (such as pigskin, human skin and rat skin) in drug transdermal penetration research, so that the bionic skin is suitable for research on transdermal penetration and absorption behaviors of drugs in external preparations such as ointment, patches and skin care products; and an alternative scheme which is more consistent with ethics, stable, economic and good in reproducibility is provided for prescription screening, quality evaluation and the like.

Disclosed herein is a new method referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. Also disclosed are stabilized spike antigens and methods of use thereof for SARS-COV-2 vaccines.

The invention discloses a recombinant protein for detecting an anti-myelin sheath related glycoprotein MAG antibody and a detection reagent of the recombinant protein, and belongs to the technical field of neural immunodiagnostics, five amino acid sites in MAG protein are subjected to specific amino acid point mutation replacement to obtain an MAG protein mutation sequence, the MAG protein mutation sequence is fused with GlcATP enzyme and HNK-1ST enzyme full-length sequences to construct a lentiviral expression vector, and the recombinant protein and the detection reagent are used for detecting the anti-myelin sheath related glycoprotein MAG antibody. According to the present invention, three genes are constructed, and are stably transfected in a host cell so as to stably express the three genes in one cell at the same time, such that the constructed recombinant protein and the wild type MAG protein have similar anti-MAG IgM antibody binding domain, and on the premise of not using GlcATP enzyme and HNK-1ST enzyme small molecule agonists, the sensitivity and the specificity of the detection of the MAG autoimmune antibody by using the CBA method are improved; the method is suitable for preparing related detection reagents for in-vitro detection of the IgM type anti-MAG antibody.

In aspects, the present disclosure provides a recombinant protein comprising (a) a rhabdoviral G glycoprotein or a functional fragment or derivative thereof, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is capable of binding to or interacting with low density lipoprotein receptor (LDLR); and (b) a cysteine rich region, wherein the cysteine rich region comprises a cysteine rich domain of LDLR, and wherein the cysteine rich region is capable of binding to or interacting with rhabdoviral G glycoprotein or a functional fragment or derivative thereof; wherein the cysteine rich region is covalently bonded to the rhabdoviral G glycoprotein or functional fragment or derivative thereof.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

The invention discloses a method for efficiently and rapidly extracting O-chain oligosaccharide. The method comprises the following steps: (1) adding sufficient saturated ammonia water into an extracted glycoprotein sample for reaction; (2) adjusting the pH value of the reacted sample to be neutral by using a 10% formic acid solution, and drying to obtain a dried sample; (3) adding ultrapure water into the dried sample, fully dissolving, centrifuging at a high speed, and taking a supernatant solution; injecting the supernatant solution into a porous graphite carbon column which is pre-treated and activated in advance, and after the supernatant solution completely passes through the carbon column, adding ultrapure water to wash the carbon column so as to remove salt ions; and eluting the O-sugar chain adsorbed on the carbon column by using an eluent, collecting the eluent, and drying to obtain the O-chain oligosaccharide. The method disclosed by the invention is simple to operate, rapid, efficient, sustainable, green and environment-friendly; the method can be widely used for extracting O-chain oligosaccharide of plant and animal samples; the problems of high extraction cost, time consumption, low yield and the like in the prior art are solved.

The application belongs to the technical field of biomedical engineering, and particularly relates to a micro-hydrogel wrapping platelets, a freeze-dried powder and a preparation method, use method and application thereof. The micro-hydrogel wrapping platelets, the micro-hydrogel is in a core-shell or multi-chamber structure, and the platelets are wrapped inside; the micro-hydrogel is formed by emulsifying a dispersed phase solution in a continuous phase solution and spontaneously physically gelling, and the platelets are wrapped inside; the micro-hydrogel can reduce the damage to the platelets caused by the freeze-drying process and rehydration, and the platelets can be stored for a long time after freeze-drying; when used, the micro-hydrogel can be dissociated by only rehydrating, centrifuging and heating, without the need of adding an additional decrosslinking agent, and the operation is convenient. The micro-hydrogel wrapping platelets has higher expression of hemostasis-related glycoprotein and lower de-sialylation degree after freeze-drying, rehydration and dissociation, and is expected to have better hemostasis ability and longer in-vivo circulation time; and is expected to greatly extend the storage time of platelets and alleviate the shortage of platelets.

The invention relates to the technical field of detection kits, in particular to a blood coagulation reaction linked lupus anticoagulant fluorescence detection kit and application thereof, the kit contains a screening-confirmation integrated reagent, a calibration product, a quality control product and an anticoagulation interference inhibitor; the integrated reagent is divided into a reagent A and a reagent B, the reagent A contains a buffer solution, recombinant snake venom thrombin, composite phospholipid, a fluorescent substrate and other components, and the reagent B contains prothrombin, calcium ions, high-concentration composite phospholipid and other components; the composite phospholipid system is formed according to a specific proportion and modifies beta2-glycoprotein I, the fluorescence enhancement-stabilization system is formed by matching a Schiff base compound with a stabilizer, the calibrator is a series of lupus anticoagulant standard substances, and the quality control substance comprises simulants with different concentrations and negative control. The anti-interference capability is high, and the influence of anti-coagulant drugs and enzyme source fluctuation is reduced; the signal amplification effect is obvious, the detection sensitivity is high and the reagent stability is good; the operation is simple and convenient, screening and confirmation are integrally completed, and a conventional fluorescence detector is adapted.

Highly potent respiratory syncytial virus (RSV) neutralizing monoclonal antibodies that specifically bind RSV fusion protein (F) or RSV attachment glycoprotein (G) are described. The monoclonal antibodies were synthesized by sequencing RSV G- and RSV F-specific B cells from a human participant of an RSV challenge study. The RSV-specific monoclonal antibodies described herein exhibit potent neutralization of RSV (IC50 as low as 0.4 ng / ml) that is superior to previously disclosed RSV neutralizing antibodies. The RSV-specific monoclonal antibodies can be used, for example, to treat, inhibit and detect RSV infection.

A preparation method for and the use of an aluminum hydroxide oxide nano-adjuvant based on calcium and silicon doping. The particle morphology of the AlOOH adjuvant is a 50-800 nm nano-particle, wherein silicon or calcium is doped in AlOOH crystal lattices, and the molar ratio of calcium or silicon to aluminum is 0.01-100:1. The preparation method comprises: synthesizing AlOOH by using an Al source, doping Ca or Si in a reaction solution by using a calcium source or a silicon source, precipitating Al(OH)3 and a dopant by adding an alkaline solution, and preparing a Ca- or Si-doped AlOOH adjuvant by means of a hydrothermal synthesis method. In a hepatitis B surface antigen and varicella-zoster virus glycoprotein E antigen model, the calcium- or silicon-doped AlOOH nano-adjuvant can simultaneously induce efficient humoral immunity and cellular immunity by means of in-vivo experiment verification of mice.

The invention discloses a preparation method of a drug-loaded glycoprotein-like network hybridization tissue engineering valve material, which comprises the following steps: carrying out a one-pot hybridization cross-linking reaction on a decellularized biological material, oxidized hyaluronic acid, phenylboronic acid grafted silk fibroin and curcumin to construct and form a drug-loaded glycoprotein-like network on the biological material; the biological material is animal tissue, including but not limited to any one of pericardium, valve, intestinal membrane, meninx and the like. The method comprises the following steps: soaking a decellularized biological material in a solution A containing OHA, SF-PBA and curcumin, and continuously oscillating for 48 hours to carry out a cross-linking reaction; and then washing with phosphate buffer saline water and distilled water to obtain the drug-loaded glycoprotein-like network hybrid tissue engineering valve material. The prepared tissue engineering valve material overcomes the defects that traditional decellularized valve and glutaraldehyde cross-linked valve materials are easy to calcify, have toxicity and are poor in immunogenicity.

The invention belongs to the technical field of immunological detection, and particularly relates to an antibody for resisting porcine pseudorabies virus glycoprotein gB and application of the antibody. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The antibody and the PRV glycoprotein gB have good reactivity, recognition specificity and binding sensitivity, the detection sensitivity and accuracy of the gB protein or the anti-gB protein antibody are improved, and an antibody tool with excellent performance is provided for qualitatively or quantitatively evaluating the immune effect of swine herd vaccines and detecting the content of porcine pseudorabies virus antigens in a sample.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

A varicella-zoster virus (VZV) nanoparticle protein, and a preparation method therefor and a use thereof. The VZV protein comprises a partial or full sequence of an amino acid sequence of an extracellular region of a VZV gE glycoprotein, with W at position 200 mutation to C and L at position 245 mutation to C in the amino acid sequence of the extracellular region of the VZV gE glycoprotein. By means of the rational optimization design of the amino acid sequence of the VZV gE protein by means of protein genetic engineering, the VZV gE recombinant protein modified with amino acid mutations has increased stability and immunogenicity compared with the VZV gE protein. Moreover, by further designing the protein structure, the VZV gE protein is repeatedly displayed on the surface of ferritin nanoparticles with the desired epitopes exposed, thereby further enhancing immunogenicity.

A series of recombinant DNA constructs and a method is disclosed for use in immunological therapy in general; and in disrupting T cell receptor (TCR), human leukocyte antigens (HLA) class I and NKG2D (Natural-Killer Group 2, member D) ligand expression in particular, with the effect of producing highly compatible autologous universal T cells for further genetically engineering for allogeneic administration. A Universal T (UT) construct is provided and used, comprising a TCR antibody fragment fused to a transmembrane domain (TMD) and ER retention domain of adenovirus early region 3 glycoprotein E3-19k (E3 / 19K) (TCR-E3 / 19K RD). The Universal T (UT) construct can hijack ERAD machinery to arrest TCR and HLA molecules in endoplasmic reticulum (ER) and facilitate their translocation into the cytoplasm for ubiquitination and degradation by proteasomes.

A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and / or ether groups; R2 is selected from [-OCH2CH2-]p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.